ICMR drops Ivermectin, Hydroxychloroquine from Covid-19 treatment guidelines
New Delhi, Sep 24: The National Task Force on Covid 19 has dropped Ivermectin and Hydroxychloroquine from revised "clinical guidance for management of adult COVID-19 patients".
The studies showed no clarity with relation to mortality benefit, no effect on length of stay, clinical recovery in case of Ivermectin medicine.
Meanwhile, the WHO panel also recommends against the use of ivermectin and hydroxychloroquine in patients with COVID-19 regardless of disease severity.
The latest guidance adds to previous recommendations for the use of interleukin-6 receptor blockers and systemic corticosteroids for patients with severe or critical COVID-19.
The WHO Guideline Development Group (GDG) panel recommends treatment combining casirivimab and imdevimab for two specific groups of patients with COVID-19.
The first recommendation is based on new evidence from three trials that have not yet been peer reviewed.
The trial show that casirivimab and imdevimab may reduce the risk of hospitalisation and duration of symptoms in those at highest risk of severe disease, such as unvaccinated, older, or immunosuppressed patients.
The second recommendation is based on data from another trial which shows that the two antibodies probably reduce deaths and the need for mechanical ventilation in seronegative patients.
This study showed that treatment with Casirivimab and imdevimab led 49 fewer deaths per 1,000 in the severely ill and 87 fewer deaths in the critically ill patients.
For all other COVID-19 patients, any benefits of this antibody treatment are unlikely to be meaningful, the panel noted.
Casirivimab and imdevimab are monoclonal antibodies that when used together bind to the SARS-CoV-2 spike protein, neutralising the virus's ability to infect cells.